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Multiresistant pathogens: The case of 
non-fermentative Gram-negative bacilli 
[ E l  Changes in classification of 
glucose-non-fermenting gram-negative bacilli 
A. Bauernfeind. Max von Pettenkofer-Institut, Munchen, Germany 
Modern taxonomy is polyphasic and incorporates genotypic, pheno- 
typic and phylogenetic markers. Genotypic characteristics are based 
on analysis of DNA or RNA molecules. rRNA is currently regarded 
as the optimal target for phylogenetic analysis as it is composed of 
lughly conserved as well as variable domains. At this time direct 
DNA-sequencing of coding regions for 16s or 23s rRNA is widely 
performed. Phenotypic procedures include all non-nucleic acid &- 
rected approaches, e.g. composition of cell wall or cellular fatty acids, 
whole cell protein analysis etc. 
Recent progress in technology allowed accumulation of new data 
leadmg to revisions in taxonomy and nomenclature (Bruckner & 
Colonna, CID, 1995) in major groups of bacteria. This holds true 
as well for glucose-non-fermenting gram-negative bacilli, e.g. Acine- 
tobacter, Pseudomom and others. Major reclassifications concern the 
genus Pseudomonac. It was subdivided into five rRNA-DNA-homol- 
ogy groups by Palleroni et al. in 1973. The genus Pseudomonac is now 
restricted to the former rRNA-group I, the species of rWA-group 
11 were transferred to the new genera Burkholdm'a and Ralrtonia, 
rRNA-group I11 became the family Comamonaduceae, rRNA-group 
IV was transferred to the genus Brevundimonas, and rWA-group V to 
Stenorrophomonac (via Xanthomonas) . 
Recently molecular procedures based on specific signature se- 
quences within the 16s or 23s rRNA have been designed to iden- 
nfy species, e.g. within the genus Burkholdm'a. They improve iden- 
dfication of species &cult to separate by phenotypic procedures. 
There are, however, examples which demonstrate the limitations of 
genetic procedures, e.g. to Merentiate between the phenotypically 
&tinct species Burkholderia cepm.a and B. vietnamiensis. T h  under- 
lines the importance of polyphasic taxonomy for A d  dassification 
and nomenclature. 
I S216 I Cross-Infection with Multiresistant 
Pseudomonas, Burkholderia and Other 
Non-Fetmenters in Cystic Fibrosis Patients 
N. H0iby. Dept. Clin. Minobiof., Rigshospitafet, Copenhagen, Denmark 
The major Gram-negative pathogens responsible for respiratory in- 
fection and mortality in cystic fibrosis (CF) are Pseudomonas amg- 
inosa and Burkholdm'a cepm'a. However, Stenohophomonas maltophilia 
and Alcaligenes xylosoxidans and a few other non-fermenting species 
are emerging as possibly important patogens due to the improved 
survial of the patients. All these species are increasingly resistant to 
most of the available antibiotics which are used extensively in CF 
patients. Difficult-to-treat strains and multiply resistant st ra ins  are 
therefore becoming an increasing problem in CF centres. Unform- 
nately, cross-infection has been documented with at least I! aeruginosa 
and B. cepacia in CF centres, in the wards, in the out-patient clinics, 
in summer-camps and during social activities such as fitness-classes. 
Even spread of epidemic s t r a i n s  between centres and between coun- 
tries and between continents has been observed. Such transmissible 
s t r a i n s  are often multiply resistant due to the selective pressure im- 
posed by the exttensive use of antibiotics in CF patients. The most 
effective preventive measure has been the use of cohorte isolation 
technique and high level of hygine in CF centres and during social 
activities. The cohorting is based on bacteriological examination of 
sputum, and e.g. patients culture-positive for I! amginosa are kept 
isolated by geography and/or time &om culture-negative patients. 
Social activities such as summer camps are completely avoided in 
some counmes. 
Acinetobacter: facts and fears 
ED. Daschner. Instihrteefor Environmental Medicine and Hospital 
Epidemiology, University Hospital, Freibug, Germany 
The presentation will cover the following fkcts: Epidemiologi- 
cal sigruficance of cutaneous, pharyngeal and digestive tract colonisa- 
tion by Acinetobucter, sunrival ofticinetobucter on dry surfaces, nosoco- 
mid outbreaks, risk factors for nosocomial colonisation, laboratory 
investigations of outbreaks, antimicrobial susceptibhlty. 
Fears: Why are hospital epidemiologists very much a.6aid of 
Acinetobucter? Why is it difficult to get rid of these organisms in hos- 
pitals when they colonise patients especially in intensive care units? 
Is there airborne spread of Acinetobacter? 
1 S218 I Moraxella and Oligella: Ecology and 
A. von Graevenitz. C H  
No abstract available. 
Pathogenicity 
Gene therapy: Where do we stand? 
I S2191 Retroviruses for Gene Delivery 
Y. Takeuchi, E Martin Molina, K. Palmer, M. Collins. Chester 
Beatty Laboratories, London, UK 
We have demonstrated that the sensitivity of retroviruses to human 
serum is controlled by the expression or alpha 1-3 galactosyl sugar 
epitopes. We have now made hgh titre packaging cells producing 
viruses resistant to human serum. We are also attempting to retar- 
get retroviruses to novel surface receptors using an insertion point 
in the MLV envelope which allows incorporation of an additional 
receptor binding domain. Our results with chimeric envelopes ex- 
pressing ligands or single chain antibodies will be &cussed. Finally, 
our strategies using retroviruses for tumour gene therapy will be 
presented. These include ex vivo modification of -our c& which 
are being used in a melanoma vaccine clinical trial and targetting 
retroviral delivery to tumour cells. 
[s2201 Genetic Approaches for HIV Infection: Promises 
D. Trono. Salk Institutefor Biological Studies, Sun diego, C A ,  USA 
First developed for heremtary &orders, gene therapy is also envi- 
sioned for the treatment of oncologic and infectious diesases. In the 
latter case, the genetic modification of cells is aimed at reducing or 
ablating the replication of a pathogen, resulting in what has been 
called an "intracellular immunization". In spite of the recent success 
of pharmaceutical approaches for the management of HIV-induced 
disease, currently available antiviral drugs are toxic, costly, and need 
to be administered for an extremely long time, if not for the pa- 
tients' entire life. Based on t h i s  premise, genetic approaches might 
represent a valid if only complementary approach for the mtment  
ofHIV mfection. The progress made towards meeting thu; objective, 
as well as the problems snll remaining and their potential solutions, 
d be discussed. 
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